Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2001-07-25
2004-10-12
Reamer, James H (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S253070, C514S253080, C514S311000, C514S312000, C514S313000, C514S314000
Reexamination Certificate
active
06803369
ABSTRACT:
FIELD OF THE INVENTION
The invention relates generally to novel methods of treating mammalian diseases using compounds that inhibit a biological activity of a topoisomerase enzymes.
BACKGROUND OF THE INVENTION
DNA topoisomerases are a group of enzymes present in all cells (both prokaryote and eukaryote) which are responsible for catalyzing topological changes in DNA. These enzymes have important functions for DNA replication, transcription and recombination, and have been shown to be essential for viability. Briefly, DNA topoisomerases supercoil and relax polynucleotides; they catalyze the reaction in which a polynucleotide, such as a double stranded DNA, wraps around the enzyme forming a complex therewith. The enzyme then catalyzes the cleavage of the double-stranded DNA and the passage of another DNA segment through the cleavage site, and then the relegation of the DNA at the cleavage site.
Eukaryotic topoisomerases are targets for antitumor agents. Some chemical agents, e.g., certain poisons and catalytic inhibitors, able to interfere with DNA topoisomerases have clinical efficacy as antitumor drugs. Many of these agents inhibit the topoisomerase at different sites, resulting in differential anticancer activity. [G. Capranico and M. Binaschi, (1998)
Biochim et Biophs. Acta
, 1400:185-1941. In particular, the quinolone group and the coumarin antibiotics, e.g., novobiocin and coumermycine A1 [A. Maxwell, (1997) “DNA Gyrase as a Drug Target”,
Trends in Microbiology
, 5:102-109] are useful anti-bacterial drugs. DNA cleavage is not required for the binding of quinolone drugs to the gyrase-DNA complex [Critchlow S. E., and Maxwell A. (1996)
Biochemistry
, 35: 7387-7393], the antibacterial activity of the quinolone group of antibacterials is, however, predicated upon the ability of these compounds to induce gyrase-mediated DNA breakage. [Drlica, K. and Zhao, X. (1997)
Microbiology and Molecular Biology Reviews
, 61:377-392]. See, also, M. D'Incalci, (1993)
Curr. Opin. Oncol
., 5:1023-1028; Y. Pommier, (1988)
Biochimie
, 80:255-270; A. Maxwell, (1996)
Nature Structural Biol
., 3(2):109-112; G. Capranico et al, Chap. 6 in “Cancer Chemotherapy and Biological Response Modifiers Annual 17”, H. M. Pinedo et al eds., 1997, Elsevier Science B. V.; and M. Couteurier et al, (1998)
Trends in Microbiology
, 6(7):269-275; Osheroff,
J. Biol. Chem
., 261:9944-9950 (1985); and Osheroff,
Pharinac. Ther
., 41:223-241 (1989)].
Among the inhibitors of human topoisomerase II are merbarone, and the bis(2,6-dioxopiperazines) such as ICR-193. While these agents do not induce topoisomerase dependent cleavage of DNA, their mechanism of action is different from the subject of this invention. Merbarone inhibits the catalytic activity of human topoisomerase 11 by blocking DNA cleavage, however DNA binding studies showed that the apparent Kd's (dissosciation constants) for enzyme to DNA binding were not substantially affected by the inhibitor, thus not consistent with the stabilisation of a ternary complex (Fortune J. M., and Osheroff N. (1998)
J. Biol. Chem
. 273 17643-50). ICRF-193 blocks ATP hydrolysis in eucaryotic topoisomerase II, an action that traps the enzyme on the DNA in a closed clamp form, preventing the protein clamp from opening, and thereby preventing release of DNA (Roca et al PNAS 91 1781-5). Point mutations, causing resistance to these drugs, however map to the ATPase of topoisomerase II (Wessel et al 1999 Cancer Research 59 3442-50). Additionally, ICRF-193 has been shown to directly bind to the dimerized ATPase domains of the yeast enzyme (Olland S., and Wang J. C. 1999
J. Biol Chem
274 21688-94).
Some of the presently used compounds for antitumor treatment based on inhibition of topoisomerases have disadvantages, such as ineffectiveness against certain cell types due to resistance mechanisms associated with their mode of action, unwanted toxicity and mutagenicity, particularly in view of the DNA cleavage activity of these compounds. Thus, there exists a need in the art for novel anti-tumor compounds, pharmaceutical compositions and methods of use thereof, especially compounds that do not exhibit DNA cleavage activity. Such compounds, compositions and methods are provided by the present invention.
SUMMARY OF THE INVENTION
In one aspect, the invention provides a method of modulating the activity of a type II topoisomerase enzyme of an aberrant cell comprising contacting the aberrant cell enzyme with a compound that inhibits the enzyme-mediated cleavage of a polynucleotide substrate. In one embodiment of this method, the compound forms a stable or transient non-covalent complex, preferably a ternary complex, with a topoisomerase enzyme and a substrate, for example a polynucleotide, particularly DNA. In another embodiment of this method, the compound inhibits the formation of the complex between a substrate and the enzyme. The aberrant cell which employs this enzyme for replication may be from a eukaryote, particularly a mammal, and especially a human. The polynucleotide substrate may be any DNA, RNA or DNA-RNA hybrid. In one embodiment, the method involves contacting an enzyme, or an aberrant cell, with the compound that inhibits replication of, or kills, the aberrant cell carrying the enzyme. Such contacting step can occur in vitro, in vivo in a mammal containing the aberrant cell or ex vivo in mammalian tissue outside of the body.
In another aspect, the invention provides a pharmaceutical composition comprising a compound that inhibits, arrests, or otherwise alters, the aberrant cell type II topoisomerase enzyme-mcdiated cleavage of a polynucleotide substrate in a pharmaceutically or physiologically acceptable carrier. In one embodiment, the compound is one that is identified by the assays described herein. Preferably, the composition has anti-tumor, and may contain other agents and/or excipients useful in the treatment of aberrant cell diseases, particularly in mammals, and especially in humans.
In yet a further aspect, the invention provides a method for treating a mammal or mammalian tissue comprising aberrant cells having a type II topoisomerase enzyme, the method comprising administering to the mammal an effective amount of an above-described pharmaceutical composition. This method involves administering the composition by a route, such as intravenous, oral, intradermal, transdermal, intraperitoneal, intramuscular, subcutaneous, by inhalation and mucosal. Preferably this method is useful for treating such diseases in a human, or in human tissue.
In another aspect, the invention provides a method for identifying an anti-tumor compound comprising screening the compound for the ability to inhibit, or otherwise alter, an aberrant cell type II topoisomerase-mediated cleavage of a polynucleotide substrate. In one embodiment, the method includes determining that a compound forms a high molecular weight higher order complex, such as a ternary complex, with the enzyme and a polynucleotide substrate.
In a preferred embodiment a method is provided for identifying an anti-tumor compound comprising screening the compound for the ability to inhibit, or otherwise alter, an aberrant cell type II topoisomerase-mediated cleavage of a polynucleotide substrate in the present of another compound. In this method compounds that potentiate the antagonism of the aberrant cell type II topoisomerase-mediated cleavage may be identified.
In another embodiment a compound may be screened against both a mammalian topoisomerase and a pathogen topoisomerase or gyrase, such as prokaryotic topoisomerase or gyrase, to identify a compound that inhibits and/or binds to both the mammalian topoisomerase and the pathogen topoisomerase or gyrase.
In another aspect of the invention are compounds of the invention not known in the art prior to the filing date of this application or an application to which this application claims benefit of priority.
In one embodiment, the method includes determining that a compound forms a high molecular weight higher order complex, s
Erskine Symon G.
Gwynn Michael
Pearson Neil David
Wilding Edwina Imogen
Gimmi Edward R.
Kinzig Charles M.
Lockenour Andrea V.
Reamer James H
SmithKline Beecham Corporation
LandOfFree
Compounds and methods for the treatment of neoplastic disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods for the treatment of neoplastic disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for the treatment of neoplastic disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3305810